1. Home
  2. QNCX vs SCLX Comparison

QNCX vs SCLX Comparison

Compare QNCX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

139.2M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$16.64

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNCX
SCLX
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.2M
139.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
QNCX
SCLX
Price
$3.80
$16.64
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$7.75
N/A
AVG Volume (30 Days)
1.1M
121.9K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$40,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$3.60
52 Week High
$4.55
$34.27

Technical Indicators

Market Signals
Indicator
QNCX
SCLX
Relative Strength Index (RSI) 64.26 41.97
Support Level $3.74 $18.34
Resistance Level $4.55 $20.62
Average True Range (ATR) 0.46 1.33
MACD 0.05 -0.40
Stochastic Oscillator 64.39 8.53

Price Performance

Historical Comparison
QNCX
SCLX

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: